- Home
- CANF vs ADVB Comparison
CANF vs ADVB Comparison
Compare CANF & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ADVB
- Stock Information
- Founded
- CANF 1994
- ADVB 2014
- Country
- CANF Israel
- ADVB United States
- Employees
- CANF N/A
- ADVB N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ADVB Medical Specialities
- Sector
- CANF Health Care
- ADVB Health Care
- Exchange
- CANF Nasdaq
- ADVB Nasdaq
- Market Cap
- CANF 9.6M
- ADVB 9.1M
- IPO Year
- CANF N/A
- ADVB 2025
- Fundamental
- Price
- CANF $0.65
- ADVB $0.56
- Analyst Decision
- CANF Strong Buy
- ADVB
- Analyst Count
- CANF 2
- ADVB 0
- Target Price
- CANF $14.50
- ADVB N/A
- AVG Volume (30 Days)
- CANF 171.1K
- ADVB 373.8K
- Earning Date
- CANF 08-26-2025
- ADVB 11-03-2025
- Dividend Yield
- CANF N/A
- ADVB N/A
- EPS Growth
- CANF N/A
- ADVB N/A
- EPS
- CANF N/A
- ADVB N/A
- Revenue
- CANF $560,000.00
- ADVB N/A
- Revenue This Year
- CANF $461.72
- ADVB N/A
- Revenue Next Year
- CANF N/A
- ADVB N/A
- P/E Ratio
- CANF N/A
- ADVB N/A
- Revenue Growth
- CANF N/A
- ADVB N/A
- 52 Week Low
- CANF $0.63
- ADVB $0.34
- 52 Week High
- CANF $3.12
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- CANF 35.47
- ADVB N/A
- Support Level
- CANF $0.64
- ADVB N/A
- Resistance Level
- CANF $0.68
- ADVB N/A
- Average True Range (ATR)
- CANF 0.02
- ADVB 0.00
- MACD
- CANF 0.01
- ADVB 0.00
- Stochastic Oscillator
- CANF 41.25
- ADVB 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.